BioResearch 바카라 사이트 디시 targets 200 global customers in 2026, driving 바카라 사이트 디시-powered decision-making in pharma and biotech

[by Ji, Yong Jun] At the recent 2026 JP Morgan Healthcare Conference held in San Francisco, one startup that drew particular attention for its active engagement was BioResearch 바카라 사이트 디시, a company founded in June 2022.

BioResearch 바카라 사이트 디시 leverages Large Language Models (LLMs) to aggregate, analyze, and deliver extensive datasets across the pharmaceutical and biotechnology sectors. Through the application of artificial intelligence (바카라 사이트 디시) technologies, the company systematically collects and interprets large-scale information encompassing deal information, drug development profiles, and clinical trial datasets.

This service is designed to enable pharmaceutical and 바카라 사이트 디시technology companies, researchers, analysts, venture capital firms, and other industry stakeholders to make more timely and informed decisions related to investments, technology licensing, and partnerships by enhancing the speed and accuracy of data-driven analysis.

In an interview with <THE BIO> conducted on January 15 (local time) at the JP Morgan Healthcare Conference in San Francisco, Jason Lee, CEO of BioResearch AI, stated, "During this year’s JP Morgan Healthcare Conference, we met with approximately 50 companies through both online and in-person meetings. When I visited San Francisco last January, we did not yet have a prototype. However, after 10 months of product development, we successfully launched our service and have since received a positive market response."

"About half of the companies we engaged with expressed such strong interest that they proceeded to discuss potential contracts on the spot. The most significant outcome of this event was the acquisition of a substantial number of solid prospective clients," Lee further added.

This outcome was attributed to a clearly defined ‘target positioning’ strategy. BioResearch AI has deliberately focused its customer base on ‘early-stage’ biotechnology companies. "Existing competitors, including global pharmaceutical database services, typically charge annual subscription fees ranging from a minimum of KRW 40 million (approximately USD 27 thousand) to as much as 100 million. However, for early-stage biotech companies with limited financial resources, such cost structures represent a significant barrier," Lee explained.

BioResearch AI has adopted a pricing policy of KRW 5-10 million per year, one-tenth of the cost of comparable existing services, while still receiving a favorable market response for the depth and sophistication of the service. "New biotech startups typically secure investments ranging from KRW 1 billion to KRW 10 billion, and access to high-quality business development (BD) information is equally critical for them. When we proposed a more accessible annual subscription fee of USD 4,000 to USD 5,000, users immediately responded by saying, 'Thank you for making this,'" Lee emphasized.

BioResearch AI has set ‘expanding its client portfolio’ as a key management goal for this year. Building on its participation in eight global industry conferences and academic meetings last year, the company plans to substantially increase its presence to approximately 30 such events this year. BioResearch AI is determined to broaden its customer contact points by actively engaging with established pharmaceutical and biotechnology hubs, including the United States, Europe, Taiwan, Japan, and China.

"Our objective for this year is to engage with at least 1,000 companies annually by conducting an average of 35 meetings per conference. By the end of this year, we aim to expand the number of subscribing companies from the current 50 (including five big pharma companies) to 200 and to secure at least 10 major pharmaceutical clients," Lee remarked. Through these initiatives, Lee explained that BioResearch AI plans to increase its subscriber base to 400 companies next year, with a long-term goal of reaching 1,000.

BioResearch AI is also implementing a new strategy for global expansion through a ‘Reseller Model’ that leverages partners with strong local networks. In markets characterized by high entry barriers or the importance of local networks, such as China and Mexico, the company is adopting a market-entry strategy based on non-exclusive licensing agreements with local public relations (PR) agencies or database service providers. Reseller agreements have already been finalized in two countries.

The company is also preparing to r바카라 사이트 디시se Series A financing in mid-year, targeting a funding round of approximately KRW 3-5 billion. The proceeds are intended to support workforce expansion and global marketing activities. In particular, BioResearch 바카라 사이트 디시 plans to double or triple its current workforce by recruiting additional BD specialists who will be deployed internationally to conduct on-site business meetings.

BioResearch 바카라 사이트 디시 is progressively enhancing its platform functionality in response to user feedback. Beginning this month, the company plans to roll out a series of targeted and practice-oriented upgrades, including the provision of direct contact points for potential partners, the proposal of original contract forms and deal terms, systematic tracking of development stages by disease area and geography, and the integration of offline sales data.

"Business development (BD) in the pharmaceutical and biotechnology sectors is fundamentally an exercise in 'investment.' Decisions regarding which technologies to adopt and where to allocate capital require a 'clear, data-driven foundation.' We aim to take a leading role in driving innovation in this area," Lee said.

“We intend to act as a ‘trigger’ that uncovers value embedded in data that others have been unable to capture. Through BioResearch AI, we will implement data- and AI-driven automation of workflows in the global pharmaceutical and biotechnology industry,” he further added.